A theory could thus be that the patients with ER + /HER2- breast cancers and nodal involvement already in the primary setting may have a greater risk of harboring a PIK3CA mutation and developing resistance to treatment, and could thus be prioritized for mutational testing. This evidence concerns the gene ERBB2 and breast cancer.